Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
Br J Dermatol
; 187(4): 599-602, 2022 10.
Article
in En
| MEDLINE
| ID: mdl-35481678
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dermatitis, Atopic
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Br J Dermatol
Year:
2022
Document type:
Article
Affiliation country:
United States